Investigating Endothelin 1 as a Marker for Kidney Issues in Sickle Cell Disease
The Role of Endothelin 1 as a Marker of Renal Impairment in Sickle Cell Disease
This study is testing if measuring a substance called endothelin 1 in urine can help understand kidney problems in children and teens with sickle cell disease.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 30 (estimated) |
| Ages | 1 Year to 18 Years |
| Sex | All |
| Sponsor | Sohag University Academic / other |
| Locations | 1 site (Sohag) |
| Trial ID | NCT06158945 on ClinicalTrials.gov |
What this trial studies
This observational study aims to explore the role of urinary endothelin 1 as a potential biomarker for renal impairment in patients with sickle cell disease (SCD) aged 1 to 18 years. By analyzing the levels of endothelin 1 in urine samples, researchers hope to identify correlations between these levels and kidney function in SCD patients. The study will include participants who meet specific inclusion criteria while excluding those with pre-existing renal diseases. The findings could enhance understanding of kidney complications in SCD and inform future management strategies.
Who should consider this trial
Good fit: Ideal candidates for this study are children and adolescents aged 1 to 18 years diagnosed with sickle cell disease.
Not a fit: Patients with pre-existing renal disease prior to the study may not benefit from this research.
Why it matters
Potential benefit: If successful, this study could lead to improved monitoring and management of renal impairment in children and adolescents with sickle cell disease.
How similar studies have performed: While the specific role of endothelin 1 in renal impairment among SCD patients is not extensively studied, similar approaches in other conditions have shown promise in identifying biomarkers for kidney function.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * The patients fulfilling all the following criteria will be included: * Patients with sickle cell disease in the age range of 1-18years. Exclusion Criteria: * Patients diagnosed to have coexistent renal disease before the study
Where this trial is running
Sohag
- Sohag university Hospital — Sohag, Egypt (Recruiting)
Study contacts
- Study coordinator: Esraa A Quenawey, resident
- Email: esraaanwar@med.sohag.edu.eg
- Phone: 01026841188
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.